Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henney FDA Will Be "Open, Timely And Responsive," Nominee Says

Executive Summary

FDA under Jane Henney would be "open, timely and responsive," the commissioner nominee told the Senate Labor & Human Resources Committee Aug. 24.

You may also be interested in...



FDA Generic Biologics Policy May Be One Change Under McClellan

FDA Commissioner-designate Mark McClellan appears to be open to establishing a generic approval system for biological products

FDA Generic Biologics Policy May Be One Change Under McClellan

FDA Commissioner-designate Mark McClellan appears to be open to establishing a generic approval system for biological products

FDA, USP Should Set Generic Biologics Standards, Sen. Hatch Proposes

Generic biologics should be a priority issue for the next FDA commissioner, Sen. Orrin Hatch (R-Utah) says

Latest Headlines
See All
UsernamePublicRestriction

Register

PS032745

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel